2.33
+3.10%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Conexeu Sciences Inc. Common Stock
Its shares trade under the ticker CNXU. It has been listed since 21 May 2026.
Conexeu Sciences Inc. develops collagen-based regenerative tissue scaffold products for applications in medical aesthetics and tissue repair. The company provides patented collagen-based scaffold products, including a collagen extracellular matrix (ECM) scaffold platform for use in medical aesthetics, wound care, tissue repair, facial rejuvenation, and large-volume body contouring such as face, breast, and butt volume restoration. Its CXU collagen gel is an investigational product targeting therapeutic and aesthetic indications, supporting tissue regeneration and aiming to minimize inflammation or fibrosis. The company's solutions are supported by preclinical and peer-reviewed data and are positioned as alternatives to conventional fillers or implants, with products currently investigational and pending regulatory clearance for certain applications. The company serves clients in the beauty, aesthetics, regenerative medicine, and medical sectors, including clinicians and professionals involved in facial rejuvenation, body contouring, wound care, and tissue repair. The company was founded in 2022 and is based in Reno, Nevada.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Listed since
- 21 May 2026
- Website
- conexeu.com ↗
- Head office
- 50 WEST LIBERTY STREET, SUITE 880, RENO, NV, 89501
- Incorporated in
- NV
- Classification
- Orthopedic, Prosthetic & Surgical Appliances & Supplies
- Filer status
- <br>Emerging growth company
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Conexeu Sciences Inc. offers patented collagen-based scaffold products for medical aesthetics and tissue repair.
- CXU collagen gel targets therapeutic and aesthetic indications with minimal inflammation or fibrosis.
- Preclinical and peer-reviewed data support Conexeu's regenerative tissue scaffold solutions.
Weaknesses
- Products are currently investigational and pending regulatory clearance for certain applications.
- The company is based in Reno, Nevada, a location not typically associated with biotech innovation.
- Conexeu Sciences Inc. was founded in 2022, a relatively new company in the regenerative medicine sector.
Opportunities
- Growing demand for regenerative medicine solutions in the beauty and aesthetics sector.
- Expansion into medical sectors like wound care and tissue repair with FDA-approved products.
- Increasing focus on collagen-based therapies in the regenerative medicine industry.
Threats
- Regulatory delays could impact the timeline for product approval and market entry.
- Competition from established biotech firms in the regenerative medicine space.
- Potential market saturation in the aesthetic and medical sectors with similar products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.